Ernexa Therapeutics Inc. (ERNA)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Ernexa Therapeutics Inc. has not issued a press release in this window.
SEC filings
All filings →Ernexa Therapeutics Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Ernexa Therapeutics Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Ernexa Therapeutics Inc. in this window.
People at Ernexa Therapeutics Inc.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for Ernexa Therapeutics Inc..